An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 14638976.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A reliable screening assay for anti-interferon beta (IFNbeta) antibodies is needed for patients with multiple sclerosis (MS) receiving IFNbeta therapy. The performance of a new ELISA method, the capture ELISA (cELISA), was assessed by comparing it to a standard IFNbeta ELISA in correlating with neutralizing antibodies measurement in 453 sera from patients with MS. The cELISA outperformed the standard ELISA, and may be a suitable screening assay for anti-IFNbeta antibodies in IFNbeta-treated patients with MS.
Medical subject headings
- Antibodies
- Enzyme-Linked Immunosorbent Assay
- Interferon-beta
- Multiple Sclerosis